Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)

Study Overview

• Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.
• Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.
• Compensation: Provided
• Study Location: Arkansas Children's Hospital
• Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Study Eligibility

• Who Can Participate: Anyone between the ages of 2-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.
• Age Range: 2-55 years
• Gender: Any

Investigators

• Site Principal Investigator: Dr. Stacie Jones; Study Coordinator: Darlene Robertson, RN
• Study Primary Investigator: Robert Wood, MD
• Co-Investigator(s): Dr. Amy Scurlock; Dr. Robert Pesek